Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).
Robert Wesolowski(The Ohio State University Wexner Medical Center), Bhuvaneswari Ramaswamy(The Ohio State University), Susan M. Geyer(Mayo Clinic in Florida), Miguel A. Villalona‐Calero(University of California, Irvine), Michael V. Knopp(University of California, Los Angeles), Ewa Mrózek(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Michael R. Grever(The Ohio State University Wexner Medical Center), Charles L. Shapiro(Tisch Hospital), Andrea Camp(The Ohio State University), Rachel M. Layman(The University of Texas MD Anderson Cancer Center), Nathan C. Hall(McGill University), Jeffrey J. Chalmers(The Ohio State University), Katharina Schregel(Brigham and Women's Hospital), Susan Ottman(The Ohio State University), Maryam B. Lustberg(Yale Cancer Center), Erin Macrae Macrae(The Ohio State University Wexner Medical Center), Meng Zhao(The Ohio State University), Jun Zhang(OSF HealthCare), Eleni Andreopoulou(Cornell University)
Cited by 16
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia
|The Journal of Experimental Medicine|2001|1.1k